Popular Trials
Behavioural Intervention
Decision Coaching for Lung Cancer Screening
This trial is testing whether navigator decision coaching, compared to enhanced usual care, results in better decision making for lung cancer screening, more screenings, and increased adherence to repeat screenings and diagnostic testing. A booster coaching session is also being tested to see if it increases adherence to repeat screenings.
Microwave Ablation
Microwave Ablation for Lung Cancer
This trial tests a new procedure that uses microwave energy to destroy lung tumors. It targets patients with a few metastatic lung tumors. The treatment involves a device that heats and kills cancer cells, guided by robotic and imaging technology for accuracy. This developing treatment option offers advantages such as larger treatment areas and shorter heating times compared to other methods.
Imaging
nCLE Aided Robotic Bronchoscopy for Lung Cancer
This trial is testing a new method that uses a tiny camera on a needle to take detailed pictures of lung tissue. It aims to help doctors accurately diagnose small growths in the lungs by providing live images of the tissue. This could improve the precision of lung biopsies and reduce the need for additional imaging tools.
Popular Filters
Trials for NSCLC Patients
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Checkpoint Inhibitor
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Trials for Non-Small Cell Lung Cancer Patients
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Checkpoint Inhibitor
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
Trials for Metastatic Patients
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Radioisotope Therapy
Rhenium Re 188 P2045 for Lung Cancer
This trial tests a new drug called Rhenium Re 188 P2045 on lung cancer patients. It aims to find a safe dose and check if it helps reduce tumors. Patients are monitored closely for side effects and tumor response.
MDM2 Inhibitor
Brigimadlin for Solid Cancers
This trial is testing a medicine called BI 907828 for adults with advanced cancer in the biliary tract, pancreas, lung, or bladder who have no other treatment options. The medicine is taken as a tablet periodically and works by blocking a protein that helps cancer cells grow.
Trials for EGFR Positive Patients
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Trials for ALK Positive Patients
Tyrosine Kinase Inhibitor
Alectinib vs Crizotinib for Non-Small Cell Lung Cancer
This trial compares two medications, alectinib and crizotinib, for treating a specific type of advanced lung cancer. The patients have not received any prior treatment for their cancer. Both drugs work by blocking a protein that helps the cancer cells grow. Alectinib has shown superior effectiveness and fewer side effects compared to crizotinib in treating this type of lung cancer.
Tyrosine Kinase Inhibitor
Crizotinib for Non-Small Cell Lung Cancer
This trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Phase 3 Trials
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Checkpoint Inhibitor
Pembrolizumab + Chemoradiation +/- Olaparib for Stage III Lung Cancer
This trial will compare the efficacy of three different treatments for unresectable, locally advanced NSCLC. Arm 1 will receive pembrolizumab concurrently with chemoradiation, followed by pembrolizumab with olaparib placebo. Arm 2 will receive the same treatment as Arm 1, but will take olaparib instead of the placebo. Arm 3 will receive concurrent chemoradiation therapy followed by durvalumab. The primary hypothesis is that pembrolizumab with concurrent chemoradiation and olaparib is superior to durvalumab with respect to PFS and OS.
Topoisomerase I inhibitors
Etoposide for Small Cell Lung Cancer
This trial uses Etoposide to treat small cell lung cancer patients. It aims to understand how differences in two specific genes affect treatment success and safety. Researchers study these genes to find links between genetic differences and how patients respond to the drug.
Alkylating agents
Radiation + Chemotherapy for Small Cell Lung Cancer
This trial is testing different radiation therapy regimens to see which is more effective in treating patients with limited-stage small cell lung cancer when given together with chemotherapy.
Tyrosine Kinase Inhibitor
Alectinib vs Crizotinib for Non-Small Cell Lung Cancer
This trial compares two medications, alectinib and crizotinib, for treating a specific type of advanced lung cancer. The patients have not received any prior treatment for their cancer. Both drugs work by blocking a protein that helps the cancer cells grow. Alectinib has shown superior effectiveness and fewer side effects compared to crizotinib in treating this type of lung cancer.
Trials With No Placebo
EGFR Inhibitor
Osimertinib + BLU-945 for Non-Small Cell Lung Cancer
This trial is testing BLU-945, a new drug that targets cancer proteins, alone or with osimertinib. It focuses on patients with specific EGFR gene mutations. The drug aims to block a protein that helps cancer cells grow.
PD-L1 Inhibitor
Coformulated Pembrolizumab/Vibostolimab for Non-Small Cell Lung Cancer
This trial is testing whether a combination of two drugs is better than just one of the drugs for overall survival and progression-free survival in people with a certain kind of cancer.
Behavioural Intervention
Communication Intervention for Dementia
This trial is testing whether or not the Jumpstart intervention can improve patient-centered outcomes for those with chronic illness. The study will specifically look at Alzheimer's disease and related dementias, but will also include other common chronic illnesses. The trial will assess the efficacy of the intervention by measuring quality of care, intensity of care outcomes, and patient- and family-reported outcomes. There will also be a mixed-methods evaluation of the implementation of the intervention to explore barriers and facilitators to future implementation and dissemination.
View More Related Trials
Frequently Asked Questions
Introduction to lung cancer
What are the top hospitals conducting lung cancer research?
In the battle against lung cancer, several hospitals have emerged as leaders in conducting groundbreaking clinical trials. One such institution is the University of California Davis Comprehensive Cancer Center, located in Sacramento. With seven active trials dedicated to lung cancer and an impressive history of 62 completed studies, this center has been making strides in understanding and treating this devastating disease since recording its first trial in 2006.
Another prominent player on the West Coast is UC San Diego Moores Cancer Center in La Jolla. This esteemed facility currently has six active lung cancer trials underway and has contributed to a total of 45 studies over time. Their commitment to advancing knowledge about lung cancer began with their inaugural study recorded in 2009.
Moving further north to Roseville, Sutter Roseville Medical Center demonstrates its dedication by offering five ongoing clinical trials for lung cancer patients while boasting a respectable record of 31 previously conducted investigations since initiating their first trial back in 2004.
The impact of clinical research extends even into smaller communities like Auburn and Cameron Park thanks to Sutter Cancer Centers Radiation Oncology Services-Auburn and Sutter Cancer Centers Radiation Oncology Services-Cameron Park respectively. Both locations are actively involved with five current lung cancer trials each, contributing significantly towards expanding our understanding of this disease through their combined tally of eighteen previous investigations dating back to their first recorded trial also occurring simultaneously ten years ago -in the year 2008.
These top hospitals across California serve as beacons of hope for individuals facing the challenges posed by lung cancer. Through relentless research efforts and participation in clinical trials, they strive not only for breakthrough treatments but also for improved outcomes and quality of life for patients affected by this condition nationwide.
Which are the best cities for lung cancer clinical trials?
When it comes to lung cancer clinical trials, several cities stand out as leaders in research and development. Sacramento, California leads the way with 29 active trials investigating treatments like Crizotinib and High Radiation Dose Therapy. Anchorage, Alaska closely follows with 25 ongoing studies focusing on innovative approaches such as High Radiation Dose Therapy and Crizotinib. Los Angeles, California also makes a significant contribution with 23 active trials exploring various treatment options including Subprotocol C2 (MET exon 14 deletion/mutation) and Cediranib Maleate. These cities offer individuals battling lung cancer access to cutting-edge clinical trials that may lead to improved outcomes in their fight against this disease.
Which are the top treatments for lung cancer being explored in clinical trials?
Lung cancer research is making strides, with several promising treatments being explored in clinical trials. Leading the pack is pembrolizumab, a drug currently involved in six active trials for lung cancer. Since its first listing in 2011, it has already been part of an impressive 190 all-time lung cancer trials. Close behind is nivolumab, also showing potential with four ongoing lung cancer studies and a total of 131 all-time trials since its introduction in 2011. Another contender worth mentioning is atezolizumab, currently being investigated in two active lung cancer trials and boasting 81 all-time clinical trials since its debut in 2013. And not to be forgotten is paclitaxel—a veteran of the field—participating in two ongoing lung cancer studies and accumulating an impressive resume of 189 all-time clinical trials since it was first listed back in 2002. These advancements bring hope for improved outcomes among patients battling this challenging disease.
What are the most recent clinical trials for lung cancer?
Recent clinical trials offer hope and potential advancements in the treatment of lung cancer. One such trial focuses on brigimadlin (BI 907828), exploring its effectiveness as a treatment option for lung cancer patients. Additionally, sitravatinib is being evaluated in a Phase 2 trial to assess its impact on lung cancer. Another study investigates the therapeutic potential of BLU-945 in both Phase 1 and Phase 2 trials for individuals with lung cancer. Furthermore, the combination of pembrolizumab and vibostolimab is being studied extensively in a Phase 3 trial, providing insight into their efficacy against this disease. Lastly, thoracic radiotherapy's role as a treatment modality continues to be explored through a Phase 3 trial aimed at optimizing patient outcomes. These ongoing clinical investigations hold promise for improved therapies in tackling the challenges posed by lung cancer.
What lung cancer clinical trials were recently completed?
Several recent clinical trials have made significant strides in advancing lung cancer research. In May 2022, Vergent Bioscience completed a trial investigating the potential of VGT-309 for treating this complex disease. Additionally, Erasca concluded their ERAS-007 trial in September 2021, while Mirati Therapeutics Inc.'s MRTX849 study reached completion in August 2021. Other important trials include Ociperlimab by BeiGene and Probiotic by Mayo Clinic, both finished in July 2021. These trials highlight the dedication of researchers towards finding innovative treatments and improving outcomes for individuals affected by lung cancer.